Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Cancer research - 15 Jun 2008

Montagut Clara, Sharma Sreenath V, Shioda Toshi, McDermott Ultan, Ulman Matthew, Ulkus Lindsey E, Dias-Santagata Dora, Stubbs Hannah, Lee Diana Y, Singh Anurag, Drew Lisa, Haber Daniel A, Settleman Jeffrey

Abstract excerpt

Activating BRAF kinase mutations arise in approximately 7% of all human tumors, and preclinical studies have validated the RAF-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase-ERK signaling cascade as a potentially important therapeutic target in this setting. Selective RAF kinase inhibitors are currently undergoing clinical development, and based on the experience with other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to In Situ Hybridization, Fluorescence
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Proto-Oncogene Proteins c-raf

Share to RNA, Small Interfering

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 18559533
DOI: 10.1158/0008-5472.CAN-07-6787
PMCID: PMC2692356

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.PMID 18559533Read ↗

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.Semantic proximity Read ↗

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.Semantic proximity Read ↗

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.Semantic proximity Read ↗

<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E MutationSemantic proximity Read ↗

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma.Semantic proximity Read ↗

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.Semantic proximity Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF InhibitorsSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.Semantic proximity Read ↗

Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.Semantic proximity Read ↗

BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells.Semantic proximity Read ↗

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.